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Abstract Human BAP31 was cleaved at both of its two
identical caspase cleavage sites in two previously reported models
of apoptosis. We show here that only the most carboxy-terminal
site is cleaved during apoptosis induced in HeLa cells by
tunicamycin, tumor necrosis factor and cycloheximide, or
staurosporine. Similar results were obtained in HL-60 cells
using Fas/APO-1 antibodies, or cycloheximide. This limited
cleavage, which is inhibited by several caspase inhibitors,
removes eight amino acids from human BAP31 including the
KKXX coat protein I binding motif. Ectopic expression of the
resulting cleavage product induces redistribution of mannosidase
II from the Golgi and prevents endoplasmic reticulum to Golgi
transport of virus glycoproteins. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Human BAP31 is an integral endoplasmic reticulum (ER)
membrane protein, which is also recycled between the ER and
the Golgi [1,2]. Its cytosolic tail ends with the KKXX coat
protein I binding motif [3]. BAP31 has been proposed to
control the export of cellubrevin from the ER [1].
Previous ¢ndings also suggest that BAP31 may take part in
the control of programmed cell death. Human BAP31 can
bind Bcl-2/Bcl-XL, caspase-8 pro-enzyme, and Ced-4 when
this nematode protein is expressed in human cells [2,4]. Dur-
ing apoptosis, induced by adenovirus E1A oncoproteins in
KB cells [2] or by photodynamic therapy in HeLa cells [5],
human BAP31 was cleaved at the two identical caspase cleav-
age sites of the cytosolic tail (Fig. 2A).
We report here that in several model systems of apoptosis,
human BAP31 is cleaved only at its most C-terminal caspase
cleavage site. We show, using caspase inhibitors, that this
cleavage is caspase dependent. When expressed ectopically,
the cleavage product (BAP3138aa) leads to the redistribution
of mannosidase II (Man II) from the Golgi into the ER and
prevented virus glycoprotein transport from the ER to the
Golgi.
2. Materials and methods
2.1. Materials
Biochemicals, enzymes, and cell culture supplies were from Sigma
(St. Louis, MO, USA) unless otherwise stated. The polyclonal Man II
antibody was a gift from K. Moremen and M. Farquhar (University
of Georgia, Athens, GA, USA). The polyclonal Semliki Forest virus
(SFV) glycoprotein antibody was a gift from S. Kera«nen (Technical
Research Centre of Finland, Espoo, Finland). The polyclonal poly-
ADP-ribose-polymerase (PARP) antibody (H-250) was purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Sec-
ondary antibodies were from Jackson ImmunoResearch Laboratories
(West Grove, PA, USA).
FuGENE-6 transfection reagent was purchased from Boehringer
Mannheim GmbH (Mannheim, Germany) and transfections were per-
formed according to the manufacturer’s instructions.
2.2. Plasmids
The wild type BAP31 sequence (the coding region and 117 bp up-
stream of the start codon and 424 bp downstream of the stop codon)
from a human placental lgt11 cDNA library (Clontech, Palo Alto,
CA, USA) was subcloned into the EcoRI site of pcDNA I/Amp (In-
vitrogen Corp., Carlsbad, CA, USA). This construct encoded a pro-
tein designated BAP31wt.
The following oligonucleotides were used to generate a construct
that encoded a protein designated BAP3138aa (BAP31 minus last
eight amino acids): 5P-TAATACGACTCACTATAGGG-3P and
5P-AAAGAATTCTTAATCTACTGCAGCCTGCAGC-3P. BAP31wt
construct was used as a template. The PCR product was subcloned
into the BamHI^EcoRI site of pcDNA I/Amp.
To generate glutathione-S-transferase (GST) or His6 fusion proteins
of BAP31, a PCR fragment encoding the C-terminal cytosolic part of
BAP31 (amino acids 151^246) was produced using the oligonucleoti-
des 5P-AAAGGATCCATGGAGGAGAATGACCAGC-3P and 5P-
AAAGAATTCTTACTCTTCCTTCTTGTCCAT-3P. The PCR prod-
uct was subcloned into the BamHI^EcoRI cut pGEX-2T (Amersham
Pharmacia Biotech AB, Uppsala, Sweden) or pRSET-A (Invitrogen
BV, NV Leek, The Netherlands) expression vectors. The resulting
constructs encoded BAP31 fusion proteins GST-BAP31 and His6-
BAP31, respectively.
2.3. Production of fusion proteins and antibodies
Expression of GST-BAP31 fusion proteins was performed in Esche-
richia coli strain BL21 according to the supplier’s instructions (Stra-
tagene, La Jolla, CA, USA). Bacteria were induced with 0.5 mM
isopropyl-L-D-thiogalactopyranoside (Promega Corp., Madison, WI,
USA). Homogenization of bacteria and puri¢cation of GST fusion
proteins were performed according to the manufacturer’s instructions
(Amersham Pharmacia Biotech AB, Uppsala, Sweden).
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To produce monoclonal BAP31 antibodies (BAP31mab), four
BALB/c female mice were immunized three times at 2 week intervals
intraperitoneal with 100 Wg of GST-BAP31 fusion proteins. The ¢rst
immunization was given in Freund’s complete adjuvant and the sub-
sequent immunizations in Freund’s incomplete adjuvant. A booster
immunization with 100 Wg of antigen in saline was given intravenous
4 days before the fusion. The spleen cells were harvested and fused to
Ag-8 myeloma cells at 10:1 ratio in the presence of 50% polyethylene
glycol 1500 (Boehringer Mannheim GmbH, Mannheim, Germany).
After the fusion, hybrid selection was performed in HAT culture
medium: 1U105 hybridoma cells per well were cultured in 0.2 ml of
RPMI 1640 supplemented with 2 mM L-glutamine, 100 U of penicil-
lin, 100 mg of streptomycin sulfate per ml, 20% (v/v) donor horse
serum (Biological Industries, Beit Haemek, Israel), 111 ng of Na py-
ruvate per ml (Bio Whittaker, Walkersville, MD, USA), MEM-non-
essential amino acids solution (Biological Industries, Beit Haemek,
Israel), and 0.1 mM hypoxanthine, 0.4 WM aminopterin, and 16 WM
thymidine (Boehringer Mannheim GmbH, Mannheim, Germany).
Antibody production was screened using enzyme-linked immunosorb-
ent assay (ELISA) as described previously [6]. His6-BAP31 fusion
proteins were produced for ELISA screening. Proteins were produced
and puri¢ed according to the manufacturer’s instructions (Qiagen
GmbH, Hilden, Germany). The product was further puri¢ed using
FPLC-anion exchange chromatography (Amersham Pharmacia Bio-
tech AB, Uppsala, Sweden). BAP31mab antibodies were a⁄nity-pu-
ri¢ed using a chromatography column where GST-BAP31 fusion pro-
teins were bound to CNBr-activated Sepharose 4B according to the
manufacturer’s instructions (Amersham Pharmacia Biotech AB, Upp-
sala, Sweden).
To generate polyclonal antibodies against the cytosolic tail of
BAP31, a New Zealand white rabbit was immunized subcutaneously
with 400 Wg of GST-BAP31 fusion proteins that were treated with
0.5% sodium dodecyl sulfate (SDS) in 85‡C for 10 min and emulsi¢ed
with 600 Wl of Freund’s complete adjuvant. The rabbit was bled every
2 weeks, and the antisera were tested by immunoblotting [7]. Five
booster immunizations were performed in the same manner as the
primary immunization except that the amount of the protein was
reduced to 200 Wg and Freund’s incomplete adjuvant was used as
adjuvant.
In the indirect immuno£uorescence staining of HeLa cells, both the
BAP31mab and the polyclonal BAP31 antibody (BAP31pab) gave
identical ER staining (not shown). BAP31mab did not stain endoge-
nous BAP31 of BHK-21 and normal rat kidney (NRK) cells at the
detection level used in this study. Both antibodies detected an V30
kDa protein from HeLa cell lysate on a Western blot corresponding
to the size of previously described human BAP31 (Fig. 1). In addition,
BAP31pab and BAP31mab were capable to recognize both of the
caspase cleavage products of BAP31 in immunoblotting (Fig. 1).
2.4. Cell culture
BHK-21, HeLa, and NRK cells were grown at 37‡C in 5% CO2 in
DME supplemented with 2 mM L-glutamine, 100 U of penicillin, 100
mg of streptomycin sulfate per ml, and 10% (v/v) fetal calf serum
(Biological Industries, Beit Haemek, Israel). HL-60 (human promye-
locytic leukemia) cells were grown in RPMI 1640 (Biological Indus-
tries, Beit Haemek, Israel) supplemented as DME. Hybridoma cells
were grown in RPMI 1640 supplemented with 2 mM L-glutamine, 100
U of penicillin, 100 mg of streptomycin sulfate per ml, 20% (v/v)
donor horse serum (Biological Industries, Beit Haemek, Israel), 111
ng of Na pyruvate per ml (Bio Whittaker, Walkersville, MD, USA),
and MEM-non-essential amino acids solution (Biological Industries,
Beit Haemek, Israel).
2.5. Induction of apoptosis and protein cleavage analyses
Medium of overnight cultures was ¢rst replaced by serum-free cul-
ture medium. Apoptosis was induced by adding to the cell medium
tunicamycin (20 Wg/ml), tumor necrosis factor (TNF) (Boehringer
Mannheim GmbH, Mannheim, Germany) (50 ng/ml), together with
cycloheximide (CHX) (10 Wg/ml), monoclonal Fas/APO-1 antibodies
(Boehringer Mannheim GmbH, Mannheim, Germany) (0.25 Wg/ml),
CHX (50 WM), or staurosporine (STS) (1 WM) [8]. All incubations
were performed at 37‡C in 5% CO2. After incubation, induced cells
and non-induced control cells were collected to Laemmli sample bu¡-
er. SDS^PAGE [9] and immunoblotting [7] were done according to
established procedures. BAP31pab and polyclonal PARP antibodies
were used. Secondary antibodies were alkaline phosphatase-conju-
gated anti-rabbit IgG antibodies.
2.6. Caspase inhibitor assays
Caspase inhibitors (Calbiochem, La Jolla, CA, USA) were added
directly from stocks to HeLa cells in serum-free culture medium 1 h
before adding TNF (20 Wg/ml), together with CHX (10 Wg/ml). After
the addition of TNF and CHX, cells were incubated for 6 h in the
presence of inhibitors and collected as described above. BAP31 and
PARP cleavage was detected as above.
2.7. Other methods
Indirect immunostaining was performed essentially as described
previously [10]. However, 0.1 M phosphate bu¡er (pH 7.4) was
used instead of phosphate-bu¡ered saline.
BHK-21 cells were infected with SFV temperature sensitive ts-1
mutant (SFV-ts1) as described previously [11]. Incubations at reduced
temperature were carried out in water baths as previously described
[10] using NaHCO3-free DME supplemented with 20 mM HEPES,
pH 7.4.
Fluorescence images were captured using an Olympus AX70 £uo-
rescence microscope (U60, 1.4 NA) with a SenSys CCD camera (Pho-
tometrics, Ltd., Mu«nchen, Germany). Images were converted using
the Image-Pro Plus version 3.0 software (Media Cybernetics, Silver
Spring, MD, USA).
3. Results
3.1. BAP31 was cleaved only at the C-terminal caspase
cleavage site in the tested apoptotic cells
We examined BAP31 cleavage during apoptosis in vivo in
HeLa cells in which apoptosis was induced either by tunica-
mycin [12] or by TNF, together with CHX [13]. In HL-60
Fig. 1. Characterization of the antibodies. Both rabbit polyclonal
antiserum BAP31pab and anti-BAP31 monoclonal antibodies
BAP31mab recognize full length and cleaved forms of BAP31. In
uninduced HeLa cells (HeLa), only full length BAP31 is seen. Both
antibodies recognize BAP31 cleaved at the most carboxy-terminal
caspase site (BAP3138aa) in HeLa cells treated with STS for 24 h
(HeLa+STS). Both BAP31pab and BAP31mab recognize also the
p20 cleavage product, as shown in the third lanes (leucocytes). To
demonstrate this, the gel sample was prepared from peripheral
blood bu¡y coat cells obtained from the Finnish Blood Transfusion
Service (Helsinki, Finland). These cells had been treated with Sendai
virus for interferon production, and therefore the majority of the
cells is likely to be in necrotic state.
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cells, apoptosis was induced either by Fas/APO-1 antibody
[14] or by CHX [13]. BAP31 cleavage was analyzed by immu-
noblotting using BAP31pab.
In the tested cells, only one cleavage product of BAP31 was
formed corresponding to the cleavage at the C-terminal cas-
pase cleavage site (to be referred to as limited cleavage of
BAP31 in this article) (Fig. 2B,C). No p20 cleavage product
was formed. PARP cleavage was used as a control for activa-
tion of caspase cascade. In every case, PARP cleavage was
observed with similar kinetics to BAP31 processing (Fig.
2B,C). To con¢rm that the observed cleavage product is a
result from the most carboxy-terminal caspase cleavage, we
transfected NRK cells with the BAP3138aa construct which
produces BAP31 protein deleted after the amino acid 238. The
protein product produced in transfected NRK cells showed
the same apparent size as the cleavage product in apoptotic
HeLa cells (Fig. 3).
Fig. 2. BAP31 and PARP cleavage in apoptotic HeLa and HL-60
cells. (A) A schematic representation of human BAP31 indicating
three transmembrane regions (TM1, TM2, and TM3), two caspase
cleavage sites (arrows), and the location of the KKXX sequence
motif (asterisk). Two possible caspase cleavage products, BA-
P3138aa and BAP31p20, are shown below. In HeLa cells (B), apo-
ptosis was induced by tunicamycin or by TNF, together with CHX,
and in HL-60 cells (C) by Fas/APO-1 antibody or by CHX. Sample
collection timepoints after induction of apoptosis are indicated.
Control cells were not induced. Both in B and C, appearance of
BAP3138aa cleavage product follows the kinetics of the PARP
cleavage.
Fig. 3. The protein expressed from BAP3138aa is identical with the
cleavage product of BAP31 in apoptotic cells. NRK control cells
treated with FuGENE (fug), BAP31wt (wt), or BAP3138aa (38aa)
only showed endogenous rodent BAP31. The intensity of the
BAP31 band increased when human BAP31wt was transfected with
FuGENE (fug+wt). BAP3138aa transfected cells (fug+38aa)
showed, additionally to endogenous rodent BAP31wt, a band corre-
sponding to human BAP31 without the last eight amino acids. This
band is equal in size as the cleavage product seen in HeLa cells
treated for 24 h with STS (lane STS 24 h), or TNF and CHX (lane
TNF+CHX 24 h). The 24 h control HeLa cells were not induced
and show only uncleaved BAP31.
Fig. 4. E¡ect of caspase inhibitors (0.002^200 WM) on BAP31 and
PARP cleavage. Apoptosis was induced by TNF/CHX treatment of
HeLa cells (no induction in 0 h control). No inhibitors were present
in the control cells. Each of the tested caspase inhibitors inhibited
both BAP31 and PARP cleavage at similar inhibitor concentrations.
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3.2. Limited cleavage of BAP31 is caspase dependent
Caspase inhibitors were used to study the involvement of
caspases in the observed BAP31 cleavage. All the tested cas-
pase inhibitors inhibited BAP31 cleavage after TNF/CHX
treatment (Fig. 4). PARP cleavage was always prevented at
the same inhibitor concentrations as BAP31 cleavage, indicat-
ing that BAP31 was always cleaved when caspase cascades
were active. Depending on the inhibitor used, a di¡erent in-
hibitor concentration was needed to e⁄ciently prevent BAP31
and PARP cleavage after TNF/CHX treatment.
3.3. In ectopic expression BAP3138aa induced redistribution
of Man II and prevented virus glycoprotein transport from
the ER to the Golgi
Ectopic expression of the caspase cleavage product BA-
P3138aa in BHK-21 or NRK cells induced formation of BA-
P3138aa positive membrane blebs (Fig. 5A,B, arrows). We
observed that the formation of these membrane structures was
accompanied by redistribution of Golgi marker Man II. In
these cells, Man II had disappeared from the Golgi and had
an ER-like staining pattern (Fig. 5C,D, note the stained nu-
clear membrane, arrow in Fig. 5C).
Similar membrane blebs have previously been observed as a
result of ectopic expression of the transmembrane fragment of
human BAP31 [1]. In the same study, cellubrevin transport
from the ER was prevented in cells having these membrane
structures. Therefore, we wanted to study whether inhibition
of ER to Golgi transport could be the reason for the redis-
tribution of Man II in BAP3138aa expressing cells.
BHK-21 cells were ¢rst transfected with BAP31wt or BA-
P3138aa using FuGENE-6 transfection reagent. After 24 h
incubation at 37‡C, the transfected cells were infected with
SFV-ts1. Then, the cells were incubated at 38‡C for 2.5 h to
arrest SFV-ts1 glycoproteins into the ER [15]. After this, the
membrane blebs of the BAP3138aa expressing cells were pos-
itive for virus glycoproteins, showing that these structures
were composed of ER membranes (Fig. 6E,F, arrows).
When the cells were further incubated at 20‡C for 2 h to allow
the ER to Golgi transport of SFV-ts1 glycoproteins [11], virus
proteins were transported to the Golgi in the BAP31wt ex-
pressing cells (Fig. 6D, arrow). In contrast, virus glycopro-
teins were retained in the ER and in the membrane blebs in
BAP3138aa expressing cells at 20‡C (Fig. 6H, arrow). No
Golgi-like virus glycoprotein staining was observed in these
cells.
4. Discussion
Previous studies have shown that in some apoptotic cells
both the caspase cleavage sites of BAP31 are processed [2,5].
The ¢ndings presented in this study show, however, that in
Fig. 5. BAP3138aa positive membrane blebs and redistribution of
Man II. BHK-21 and NRK cells were transfected with BAP3138aa
using FuGENE-6 transfection reagent and were double stained with
BAP31mab and anti-Man II antibodies after 24 h expression. The
arrows in A and B indicate BAP3138aa positive membranes. Note
the disappearance of the Man II positive Golgi structure in cells ex-
pressing BAP3138aa. Bars, 10 Wm.
Fig. 6. Ectopic expression of BAP3138aa prevents ER to Golgi
transport of SFV-ts1 glycoproteins. After ¢xation, the cells were
double stained with BAP31mab and anti-SFV antibodies. The upper
panel (A^D) demonstrates the transport of SFV-ts1 glycoproteins to
the Golgi in BAP31wt expressing cells (arrow in D). The lower pan-
el (E^H) demonstrates that the transport of SFV-ts1 glycoproteins
to the Golgi is prevented in the cells having BAP3138aa positive
membrane blebs. Note the normal Golgi transport of SFV glycopro-
teins in the absence of BAP3138aa expression (shown in H). Bars,
10 Wm.
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many other models of apoptosis, human BAP31 is processed
only at its most C-terminal caspase cleavage site. This varia-
tion in the cleavage of BAP31 raises the possibility that the
function of BAP31 during apoptosis could be controlled by
alternative caspase cleavage.
Ectopic expression of BAP3138aa caspase cleavage prod-
uct induced formation of BAP3138aa positive membrane
blebs and caused Man II to redistribute into the ER. In a
previous study, Cole et al. [16] presented evidence that Golgi
proteins are constitutively recycled into the ER. This kind of
recycling would result in the redistribution of Golgi proteins
into the ER if the transport from the ER is prevented. This
could be the explanation for Man II redistribution after BA-
P3138aa expression, since the anterograde transport was pre-
vented in the cells expressing BAP3138aa: SFV-ts1 glycopro-
teins were not transported from the ER to the Golgi. An
interesting subject for further studies is to solve whether this
transport defect is responsible for some alterations that take
place in dying cells during programmed cell death. Further
studies are also required to ¢nd out if there are any di¡erences
in the function of the two caspase cleavage products of
BAP31.
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